{"id":"warfarin-titrated-to-an-inr-of-2-5-3-0","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Bleeding"},{"rate":"5-10%","effect":"Nosebleeds"},{"rate":"5-10%","effect":"Bruising"},{"rate":"1-5%","effect":"Gastrointestinal bleeding"},{"rate":"<1%","effect":"Hemorrhagic stroke"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Warfarin acts as an anticoagulant by inhibiting the gamma-carboxylation of vitamin K-dependent clotting factors, which are essential for blood coagulation. This results in a decrease in the production of these clotting factors, leading to a reduction in blood clotting.","oneSentence":"Warfarin inhibits the synthesis of vitamin K-dependent clotting factors in the liver.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:59.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation"},{"name":"Treatment and prevention of deep vein thrombosis and pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT00645853","phase":"PHASE2","title":"Long-term Safety in Atrial Fibrillation Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-10","conditions":"Persistent or Permanent Nonvalvular Atrial Fibrillation","enrollment":523},{"nctId":"NCT00007683","phase":"PHASE3","title":"Warfarin and Antiplatelet Therapy in Chronic Heart Failure","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"1998-10","conditions":"Heart Failure","enrollment":1587}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Warfarin titrated to an INR of 2.5-3.0","genericName":"Warfarin titrated to an INR of 2.5-3.0","companyName":"US Department of Veterans Affairs","companyId":"us-department-of-veterans-affairs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Warfarin inhibits the synthesis of vitamin K-dependent clotting factors in the liver. Used for Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, Treatment and prevention of deep vein thrombosis and pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}